Who are Strontium Ranelate + Ca/Vitamin-D's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/strontium-ranelate-ca-vitamin-d.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Strontium Ranelate + Ca/Vitamin-D — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Strontium Ranelate + Ca/Vitamin-D (Strontium Ranelate + Ca/Vitamin-D) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Bone-active agent / Antiosteoporotic combination. Area: Orthopedics / Rheumatology.

marketed Bone-active agent / Antiosteoporotic combination Osteoblasts and osteoclasts (non-receptor mediated); calcium-sensing receptor (vitamin D component) Orthopedics / Rheumatology Small molecule Live · refreshed every 30 min

Target snapshot

Strontium Ranelate + Ca/Vitamin-D (Strontium Ranelate + Ca/Vitamin-D) — Medical University of Vienna. Strontium ranelate promotes bone formation and reduces bone resorption, while calcium and vitamin D provide essential minerals and cofactors for bone mineralization and calcium homeostasis.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Strontium Ranelate + Ca/Vitamin-D TARGET	Strontium Ranelate + Ca/Vitamin-D	Medical University of Vienna	marketed	Bone-active agent / Antiosteoporotic combination	Osteoblasts and osteoclasts (non-receptor mediated); calcium-sensing receptor (vitamin D component)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Bone-active agent / Antiosteoporotic combination class)

Medical University of Vienna · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Strontium Ranelate + Ca/Vitamin-D — Competitive Intelligence Brief. https://druglandscape.com/ci/strontium-ranelate-ca-vitamin-d. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab